Human OX40 Ligand/TNFSF4 PE-conjugated Antibody Summary
Accession # P23510
Complete Your Research
Complete Your Experiment
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of OX40 Ligand/TNFSF4 in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) treated with Recombinant Human GM-CSF (Catalog # 215-GM) and LPS for 48 hours were stained with Mouse Anti-Human OX40 Ligand/TNFSF4 PE-conjugated Monoclonal Antibody (Catalog # FAB10541P, filled histogram) or isotype control antibody (Catalog # IC002P, open histogram). View our protocol for Staining Membrane-associated Proteins.
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: OX40 Ligand/TNFSF4
OX40 Ligand (OX40L), also known as gp34, is a type II transmembrane glycoprotein designated TNFSF4 within the TNF superfamily. Human OX40L cDNA encodes a 183 amino acids (aa) polypeptide with an amino-terminal cytoplasmic domain (aa 1-23) and a carboxy-terminal extracellular domain (aa 51-183). It shares 46% aa sequence identity with the mouse counterpart. OX40L is expressed on the surface of activated B cells, T cells, dendritic cells and endothelial cells. Like other TNF superfamily members, membrane-bound OX40 Ligand exists as a homotrimer. OX40L binds to OX40 (CD134), a member of the TNF receptor superfamily that is expressed predominantly on activated CD4+ T cells. OX40 Ligand is one of the group of co-stimulatory molecules in the immune system that includes B7, CD40 Ligand, CD30 Ligand, CD27 Ligand and 4-1BB Ligand. OX40 appears as a late activation-induced T cell surface antigen, and its major function of OX40-OX40L interaction may be to transmit a late co-stimulatory signal to promote the survival and proliferation of activated CD4+ T cells and prolong the immune response. Engagement of OX40 on activated T cells in situ in tumors has been shown to augment immune responses and subsequent tumor regression.
- Godfrey, W.R. et al. (1994) J. Exp. Med. 180:757.
- Baum, P.R. et al. (1994) EMBO J. 13:3992.
- Al-Shamkhani, A. et al. (1997) J. Biol. Chem. 272:5275.
- Kjaergaard, J. et al. (2000) Cancer Res. 60:5514.
Citations for Human OX40 Ligand/TNFSF4 PE-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 2
Filter your results:
Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells.
Authors: Wang C, Yi T, Qin L, Maldonado R, von Andrian U, Kulkarni S, Tellides G, Pober J
J Clin Invest, 2013;123(4):1677-93.
Sample Types: Whole Cells
Applications: Flow Cytometry
Upregulation of OX40 ligand on monocytes contributes to early virological control in patients with chronic hepatitis C.
Authors: Zhang J, Wu X, Yang B, Wang Y, Feng G, Jiang T, Zeng Q, Xu X, Li Y, Jin L, Lv S, Zhang Z, Fu J, Wang F
Eur J Immunol, 2013;43(7):1953-62.
Sample Types: Whole Blood
Applications: Flow Cytometry
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human OX40 Ligand/TNFSF4 PE-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human OX40 Ligand/TNFSF4 PE-conjugated Antibody and earn rewards!
Have you used Human OX40 Ligand/TNFSF4 PE-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image